Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,666 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.01, for a total transaction of $133,494.66. Following the completion of the sale, the insider owned 1,144,462 shares of the company’s stock, valued at $9,167,140.62. This trade represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total transaction of $133,827.98.
• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.06, for a total transaction of $101,002.02.

Xeris Biopharma Trading Up 0.7%

NASDAQ:XERS opened at $8.19 on Wednesday. The company has a market capitalization of $1.41 billion, a P/E ratio of 136.50 and a beta of 0.66. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The firm has a fifty day simple moving average of $7.59 and a 200-day simple moving average of $6.79.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The firm had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. On average, equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at about $25,000. KBC Group NV purchased a new position in Xeris Biopharma during the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd lifted its holdings in Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.